Disease Systems Analysis of Bone Mineral Density and Bone Turnover Markers in Response to Alendronate, Placebo, and Washout in Postmenopausal Women.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed (1999) 8.87

Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med (2006) 7.45

PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed (2005) 6.36

Mechanisms of anabolic therapies for osteoporosis. N Engl J Med (2007) 3.33

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66

Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed (2010) 2.34

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. Ann Intern Med (1999) 2.01

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81

Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol (2004) 1.77

Osteoporosis and its management. BMJ (2006) 1.75

A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling. Bone (2009) 1.57

Disease system analysis: basic disease progression models in degenerative disease. Pharm Res (2005) 1.45

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2002) 1.41

Predicting nonlinear changes in bone mineral density over time using a multiscale systems pharmacology model. CPT Pharmacometrics Syst Pharmacol (2012) 1.06

Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab (2005) 0.95

Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin Pharmacokinet (2010) 0.93

Coping with time scales in disease systems analysis: application to bone remodeling. J Pharmacokinet Pharmacodyn (2011) 0.93

FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? CPT Pharmacometrics Syst Pharmacol (2015) 0.92

Current, new and future treatments of osteoporosis. Rheumatol Int (2010) 0.92

Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study. J Clin Endocrinol Metab (2004) 0.90

Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women. Biopharm Drug Dispos (2011) 0.83

In vitro and in vivo responses to high and low doses of nitrogen-containing bisphosphonates suggest engagement of different mechanisms for inhibition of osteoclastic bone resorption. Calcif Tissue Int (2013) 0.82

Application of a mechanism-based disease systems model for osteoporosis to clinical data. J Pharmacokinet Pharmacodyn (2013) 0.81

Associations between body morphology and bone mineral density in premenopausal women. Eur J Epidemiol (1997) 0.81

Preconditioning of Nonlinear Mixed Effects Models for Stabilisation of Variance-Covariance Matrix Computations. AAPS J (2016) 0.81

Application of a Systems Pharmacology-Based Placebo Population Model to Analyze Long-Term Data of Postmenopausal Osteoporosis. CPT Pharmacometrics Syst Pharmacol (2015) 0.77